Xenon Pharmaceuticals Inc. (XENE)

Trade XENE now with
1/14/2021 8:10:19 AM Xenon Anticipate Number Of Key Milestone Events Looking Ahead To 2021
10/8/2020 8:07:35 AM Xenon Pharma Gets FDA Feedback And Is On Track To Initiate XEN496 Phase 3 Clinical Trial Before Year-End
8/17/2020 8:40:13 AM Xenon Appoints Chris Von Seggern As Chief Commercial Officer
3/31/2020 8:33:52 AM Xenon Provides Corporate Update On Proprietary And Partnered Programs
12/2/2019 7:33:15 AM Neurocrine Biosciences, Xenon Pharma Announce License Agreement To Develop First-in-class Treatments For Epilepsy
1/28/2019 8:10:53 AM Xenon Provides Regulatory Updates On XEN007 And XEN1101
1/6/2019 9:07:08 PM Xenon Pharma Provides Corporate Update And Outlines Anticipated Key Milestone Events In 2019
12/3/2018 7:48:01 AM Xenon Announces Final Results Of XEN1101 Phase 1 Trial And Update On XEN901 Phase 1 Clinical Trial
9/17/2018 4:22:14 PM Xenon Pharmaceuticals Announces Closing Of Its $63 Mln Public Offering Of Common Shares
9/12/2018 9:20:44 PM Xenon Pharma Announces Pricing Of Its Underwritten Public Offering Of 4.50 Mln Shares At $14.00/shr
9/12/2018 4:02:51 PM Xenon Pharmaceuticals Announces Proposed Public Offering Of Common Shares
9/6/2018 6:39:51 AM Xenon Expands Ion Channel Neurology Pipeline With Addition Of XEN496, A “Phase 3 Ready” Potassium Channel Modulator
8/29/2018 6:06:07 AM Xenon Announces Positive XEN1101 Pharmacodynamic Data From Phase 1b TMS Study